Clinical Research Directory

Browse clinical research sites, groups, and studies.

1 clinical study listed.

Healthy volunteers

Filters:

NUP98 Fusion-positive Acute Myeloid Leukemia

Tundra lists 1 NUP98 Fusion-positive Acute Myeloid Leukemia clinical trial. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

ACTIVE NOT RECRUITING

NCT07437170

Selinexor Combined With Induction Chemotherapy for Children With NUP98-positive AML

This is a prospective, single-arm, open-label clinical study to evaluate the efficacy and safety of Selinexor combined with a standardized induction chemotherapy regimen (ZJCH-AML) for children with NUP98-fusion positive Acute Myeloid Leukemia (AML). NUP98-fusion positive AML is a high-risk subtype in pediatric patients, characterized by poor prognosis and high relapse rates under traditional chemotherapy. Preliminary research suggests that Selinexor, an XPO1 inhibitor, can selectively inhibit NUP98-driven leukemia cells. This study aims to determine if adding Selinexor to standardized chemotherapy can increase the complete remission rate and improve the overall survival for these specific high-risk patients.

Gender: All

Ages: 1 Year - 18 Years

Updated: 2026-02-27

1 state

Acute Myeloid Leukemia

Pediatric Acute Myeloid Leukemia

NUP98 Fusion-positive Acute Myeloid Leukemia